Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US...

21

Transcript of Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US...

Page 1: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 2: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 3: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 4: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 5: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 6: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 7: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 8: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 9: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 10: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 11: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 12: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 13: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 14: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 15: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 16: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 17: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 18: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 19: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 20: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,
Page 21: Therapeutic Anti- IL- 20 mAb for Rheumatoid Arthritis · JAK-I inhibitor ABBV/E(RA) Aug. 2019, US JAK-1/2 inhibitor Pan-JAK inhibitor Aste//as Pharma (RA) 2017 EW 2018 US Mar. 2019,

JAK/STAT Signaling - file.medchemexpress.com · 1 Inhibitors, Agonists, Screening Libraries JAK/STAT Signaling The Janus kinase (JAK)/signal transducer and activator of transcription

JAK/STAT Signaling - file.medchemexpress.com · 1 Inhibitors, Agonists, Screening Libraries JAK/STAT Signaling The Janus kinase (JAK)/signal transducer and activator of transcription

Long non-coding RNA RP11-468E2.5 curtails colorectal ... › track › pdf › 10.1186 › s13046-019-1428-0RP11-468E2.5, AG490 (an inhibitor of the JAK/STAT signaling pathway), or

Long non-coding RNA RP11-468E2.5 curtails colorectal ... › track › pdf › 10.1186 › s13046-019-1428-0RP11-468E2.5, AG490 (an inhibitor of the JAK/STAT signaling pathway), or

Maximizing Patient Outcomes in Myelofibrosis: Stem Cell Transplantation in the JAK Inhibitor Era

Maximizing Patient Outcomes in Myelofibrosis: Stem Cell Transplantation in the JAK Inhibitor Era

Se Chang Kwon - hanmi.co.kr · (e.g., SYK, JAK) Next generation FLT3 Inhibitor overcoming resistance ... 2011 2012 2013 2014 2015 RAF inhibitor Exclusive Licensing WW ex. Korea Hyalrheuma

Se Chang Kwon - hanmi.co.kr · (e.g., SYK, JAK) Next generation FLT3 Inhibitor overcoming resistance ... 2011 2012 2013 2014 2015 RAF inhibitor Exclusive Licensing WW ex. Korea Hyalrheuma

Trailers research jak

Trailers research jak

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell ... › content › clincanres › 23 › 9 › 2313.full.pdfPublished OnlineFirst October 3, 2016; DOI: 10.1158/1078-0432.CCR-16-1662

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell ... › content › clincanres › 23 › 9 › 2313.full.pdfPublished OnlineFirst October 3, 2016; DOI: 10.1158/1078-0432.CCR-16-1662

EXTENDED REPORT The JAK inhibitor tofacitinib suppresses ...

EXTENDED REPORT The JAK inhibitor tofacitinib suppresses ...

Jak uniknąć?

Jak uniknąć?

Phase II study of the JAK kinase inhibitor ruxolitinib in patients

Phase II study of the JAK kinase inhibitor ruxolitinib in patients

Long-term survival in patients treated with ruxolitinib for ......This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in

Long-term survival in patients treated with ruxolitinib for ......This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in

Presentation Title JAK Inhibitor CTP-543 Achieves Primary ... · JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata An interim analysis of 4 and 8

Presentation Title JAK Inhibitor CTP-543 Achieves Primary ... · JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata An interim analysis of 4 and 8

The suppressor of cytokine signaling–1 (SOCS1) is a novel ...ing in cardiac myocyte antiviral defense and a negative role of an intrinsic JAK inhibitor, the sup- ... genic expression

The suppressor of cytokine signaling–1 (SOCS1) is a novel ...ing in cardiac myocyte antiviral defense and a negative role of an intrinsic JAK inhibitor, the sup- ... genic expression

JOIST JAK SYSTEM SPECIFICATIONS Jak...Components Joist Jak™ System Components Joist Jak™ The Joist Jak™ is the main component of the Joist Jak™ deck system. Joist Jaks™ come

JOIST JAK SYSTEM SPECIFICATIONS Jak...Components Joist Jak™ System Components Joist Jak™ The Joist Jak™ is the main component of the Joist Jak™ deck system. Joist Jaks™ come

In vitro and in vivo characterization of the JAK1 ... · rheumatoid arthritis. Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has

In vitro and in vivo characterization of the JAK1 ... · rheumatoid arthritis. Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has

Jak and Daxter

Jak and Daxter

Compressors Jak 9'03

Compressors Jak 9'03

strategie školy na období · argumentovat a diskutovat, jak přijímat a odmítat, jak se nebát říci svůj názor, jak využívat volný þas, jak pochopit sám sebe, jak poznat

strategie školy na období · argumentovat a diskutovat, jak přijímat a odmítat, jak se nebát říci svůj názor, jak využívat volný þas, jak pochopit sám sebe, jak poznat

SUPPLEMENTARY MATERIALS 1) Supplemental Methods · Dkk1 150 µg/mL 150 ng/mL Wnt GDC0941 100 mM 1 µM PI3K Jak Inhibitor I 10 mM 2 µM Jak family LDN193189 1 mM 2.5 µM BMP type 1

SUPPLEMENTARY MATERIALS 1) Supplemental Methods · Dkk1 150 µg/mL 150 ng/mL Wnt GDC0941 100 mM 1 µM PI3K Jak Inhibitor I 10 mM 2 µM Jak family LDN193189 1 mM 2.5 µM BMP type 1

Kinase inhibitors in rheumatoid arthritis: JAK/ STAT ...ankararomatoloji.com/Sunumlar/2011/9_Kinase_inhibitor_in_RA-JAK... · Kinase inhibitors in rheumatoid arthritis: JAK/ STAT

Kinase inhibitors in rheumatoid arthritis: JAK/ STAT ...ankararomatoloji.com/Sunumlar/2011/9_Kinase_inhibitor_in_RA-JAK... · Kinase inhibitors in rheumatoid arthritis: JAK/ STAT

JAK-Jan- 2011

JAK-Jan- 2011